Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortization of GoodwillAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maravai Lifesciences Holdings (MRVI) Cash from Operations: 2019-2024

Historic Cash from Operations for Maravai Lifesciences Holdings (MRVI) over the last 6 years, with Dec 2024 value amounting to $7.5 million.

  • Maravai Lifesciences Holdings' Cash from Operations fell 215.33% to -$15.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$49.4 million, marking a year-over-year decrease of 265.40%. This contributed to the annual value of $7.5 million for FY2024, which is 94.09% down from last year.
  • Latest data reveals that Maravai Lifesciences Holdings reported Cash from Operations of $7.5 million as of FY2024, which was down 94.09% from $126.2 million recorded in FY2023.
  • In the past 5 years, Maravai Lifesciences Holdings' Cash from Operations registered a high of $536.0 million during FY2022, and its lowest value of $7.5 million during FY2024.
  • For the 3-year period, Maravai Lifesciences Holdings' Cash from Operations averaged around $223.2 million, with its median value being $126.2 million (2023).
  • In the last 5 years, Maravai Lifesciences Holdings' Cash from Operations surged by 531.09% in 2020 and then crashed by 94.09% in 2024.
  • Over the past 5 years, Maravai Lifesciences Holdings' Cash from Operations (Yearly) stood at $152.2 million in 2020, then spiked by 142.18% to $368.6 million in 2021, then surged by 45.42% to $536.0 million in 2022, then plummeted by 76.45% to $126.2 million in 2023, then plummeted by 94.09% to $7.5 million in 2024.